Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 1330

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1A
Chunk 1330
---
/or on the identification and successful completion of equity or debt financing and the achievement of profitable operations
at an indeterminate time in the future. There can be no assurances that we will be successful in completing these collaborations or alliances,
equity or debt financing or in achieving profitability. As such, there can be no assurance that we will be able to continue as a going
concern.

Substantial
doubt about our ability to continue as a going concern may materially and adversely affect the price per share of our common stock, and
it may be more difficult for us to obtain financing. If potential collaborators decline to do business with us or potential investors
decline to participate in any future financing due to such concerns, our ability to increase our cash position may be limited. The perception
that we may not be able to continue as a going concern may cause others to choose not to deal with us due to concerns about our ability
to meet our contractual obligations. If we are unable to continue as a going concern, you could lose all or part of your investment in
our Company.

Given
our lack of current cash flow, we will need to raise additional capital. If we are unable to raise a sufficient amount of capital when
needed in required amounts and on acceptable terms or at all, we may be forced to delay, limit or eliminate some or all of our research
programs, product development activities and commercialization efforts.

Since
we will be unable to generate sufficient, if any, cash flow to fund our operations for the foreseeable future, we will need to seek additional
equity or debt financing to provide the capital required to maintain or expand our operations.

There
can be no assurance that we will be able to raise sufficient additional capital on acceptable terms or at all. If such additional financing
is not available on satisfactory terms, or is not available in sufficient amounts, we may be required to delay, limit or eliminate some
or all of our research programs, product development activities and commercialization efforts, and our ability to achieve our business
objectives, our competitiveness, and our business, financial condition and results of operations may be materially adversely affected.
In addition, we may be required to grant rights to develop and market product candidates that we would otherwise prefer to develop and
market ourselves. Our inability to fund our business could lead to the loss of your investment.

Our
future capital requirements will depend on many factors, including, but not limited to:

    ●
    the
    scope, progress, results and costs of